Literature DB >> 1718761

Rejection of bone marrow cell allografts by natural killer cell subsets: 5E6+ cell specificity for Hh-1 determinant 2 shared by H-2d and H-2f.

C L Sentman1, V Kumar, M Bennett.   

Abstract

The 5E6 antigen, defined by anti-5E6 mAb, is expressed on one-half of murine natural killer (NK) cells, and we have previously demonstrated (C. L. Sentman et al., J. Exp. Med. 1989. 170: 1991) that 5E6+ NK cells are necessary for the rejection of BALB/c (Hh-1d) but not C567BL/6 (Hh-1b) bone marrow cells (BMC). In experiments described here, we have characterized the specificity of 5E6+ and 5E6- NK cell subsets for hemopoietic histocompatibility-1 (Hh-1) antigens. Prospective recipient mice were treated with anti-5E6 mAb and challenged with BMC from a variety of donors. In addition, H-2d/Hh-1d C.B-17 scid 5E6+ or 5E6- NK cells were adoptively transferred into irradiated, NK cell-depleted hosts and challenged with H-2b/Hh-1b BMC. The data indicate that the 5E6+ NK cells are necessary for the rejection of only those BMC that express the Hh-1 determinant 2 shared by H-2d and H-2f haplotypes of strains BALB/c (d), A.Ca (f), and B10.M (f). No reactivity to other Hh-1 antigens resides in the 5E6+ population. In contrast, the ability of NK cells to lyse H-2d or H-2b tumor cells was independent of 5E6 expression. These results suggest that the 5E6 molecule is likely to be important in the specific recognition and rejection of BMC that express Hh-1 determinant 2, and is probably not involved in recognition of "tumor target cell structures".

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718761     DOI: 10.1002/eji.1830211125

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  NKG2D in NK and T cell-mediated immunity.

Authors:  Kouetsu Ogasawara; Lewis L Lanier
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

2.  Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.

Authors:  Kouetsu Ogasawara; Jonathan Benjamin; Rayna Takaki; Joseph H Phillips; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

3.  Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice.

Authors:  H W Rogers; E R Unanue
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

4.  Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand.

Authors:  M Y Olsson; K Kärre; C L Sentman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  An autosomal dominant locus, Nka, mapping to the Ly-49 region of a rat natural killer (NK) gene complex, controls NK cell lysis of allogeneic lymphocytes.

Authors:  E Dissen; J C Ryan; W E Seaman; S Fossum
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

6.  Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes.

Authors:  N M Valiante; G Trinchieri
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

7.  Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.

Authors:  Michel van Gelder; Ariane Vanclée; Catharina H M J van Elssen; Pierre Hupperets; Lotte Wieten; Gerard M Bos
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

8.  Control of rat natural killer cell-mediated allorecognition by a major histocompatibility complex region encoding nonclassical class I antigens.

Authors:  J T Vaage; C Naper; G Løvik; D Lambracht; A Rehm; H J Hedrich; K Wonigeit; B Rolstad
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

9.  Cloning and characterization of 5E6(Ly-49C), a receptor molecule expressed on a subset of murine natural killer cells.

Authors:  E R Stoneman; M Bennett; J An; K A Chesnut; E K Wakeland; J B Scheerer; M J Siciliano; V Kumar; P A Mathew
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.